Shares of Opko Health (OPK) – Get Report jumped on Tuesday after the drugmaker said it would start a Phase 2 clinical trial of rayaldee, a potential treatment for mild-to-moderate coronavirus.
The trial will be a randomized double-blind placebo-controlled study that is expected to enroll about 160 subjects. Many of the participants will have stage 3 or 4 kidney disease and are at higher risk for developing more serious illness.
The trial will randomize outpatients in a 1:1 ratio for four weeks of treatment with rayaldee or placebo, with another two weeks of follow-up.
One primary endpoint of the trial is the time to resolution of a patient’s coronavirus symptoms.
Secondary endpoints for the trial include incidence of emergency-room or urgent-care visits, oxygen saturation below 94%, need for and duration of hospitalizations, requirement for ventilators, mortality rate, and severity and duration of illness evidenced by quality-of-life measures.